Unlock Exclusive Discounts & Flash Sales! Click Here to Join the Deals on Every Wednesday!
The incidence of hematological malignancies has been increasing over the past 30 years and accounts for about 9 percent of all cancers. Lymphomas are the most common type of hematologic malignancies. B-cell lymphomas are more common than T-cell lymphomas, accounting for approximately 85% of all non-Hodgkin lymphomas (NHL). CD19 is a transmembrane glycoprotein of the immunoglobulin (Ig) superfamily. It is expressed at different stages of B-cell development, beginning at the pre-B-cell stage and ending in early plasma cells. In addition, CD19 is widely expressed in B-cell malignancies, including CD20 positive [e.g., NHL and B chronic lymphocytic leukemia (B-ClL) ] and low or negative CD20 [e.g., B acute lymphocytic leukemia].